<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118871</url>
  </required_header>
  <id_info>
    <org_study_id>FAST1.0</org_study_id>
    <nct_id>NCT01118871</nct_id>
  </id_info>
  <brief_title>The First Failure Study</brief_title>
  <acronym>FAST</acronym>
  <official_title>A Randomised, Open Label, Prospective Study to Assess Two Different Therapeutic Strategies Following First Treatment Failure in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to look at two different antiretroviral treatment options in&#xD;
      individuals who are about to commence their second antiretroviral treatment.&#xD;
&#xD;
      This study will assess important clinical and laboratory differences between these two&#xD;
      therapeutic options. Potential differences include: differences in body fat distribution, in&#xD;
      lipid parameters, in adherence and in neurocognitive (brain) function. This study is looking&#xD;
      to show differences in body fat distribution between the two study treatment arms.&#xD;
      Differences in lipids, viral load, adherence, cardiac and bone biomarkers and neurocognitive&#xD;
      function will also be assessed. There is also a lumbar puncture sub study participants can&#xD;
      also take part in.&#xD;
&#xD;
      The total duration of involvement in the trial will be up to 96 weeks (approximately 2 years)&#xD;
      plus a screening visit 1 - 4 weeks prior to the start of the study. Including visit the&#xD;
      clinic on 12 occasions (screening visit, baseline visit, weeks 2, 4, 8, 12, 24, 36, 48, 64,&#xD;
      80 and 96)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in peripheral and central adipose tissue</measure>
    <time_frame>week 48 and 96</time_frame>
    <description>As measured by DEXA, between treatment arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients &lt;50 copies HIV-1 RNA/mL</measure>
    <time_frame>96 weeks</time_frame>
    <description>At all study points to weeks 48 and 96 between treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline of absolute CD4+ T cell count</measure>
    <time_frame>96 weeks</time_frame>
    <description>between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to change in randomly assigned therapy</measure>
    <time_frame>96 weeks</time_frame>
    <description>between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline Lipodystrophy Case Definition score</measure>
    <time_frame>96 weeks</time_frame>
    <description>Between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in fasting lipid and glycaemia parameters</measure>
    <time_frame>96 weeks</time_frame>
    <description>between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in cardiac and bone biomarker levels</measure>
    <time_frame>Week 96</time_frame>
    <description>between treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>â€¢ Comparison of total number of patients with any serious adverse events (SAEs), and the cumulative incidence of SAEs</measure>
    <time_frame>96 week s</time_frame>
    <description>Between the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of genotypic HIV resistance associated with virological treatment failure</measure>
    <time_frame>96 weeks</time_frame>
    <description>Across the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe aspects of immune reconstitution disease (IRD)</measure>
    <time_frame>96 weeks</time_frame>
    <description>Across the treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of quality of life and results of adherence questionnaires</measure>
    <time_frame>96 weeks</time_frame>
    <description>Between the treatment arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NRTI sparing arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir, Ritonavir, Truvada</intervention_name>
    <description>Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily</description>
    <arm_group_label>Standard of care</arm_group_label>
    <other_name>Prezista</other_name>
    <other_name>Norvir</other_name>
    <other_name>Truvada</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir, Ritonavir and Etravirine</intervention_name>
    <description>Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily</description>
    <arm_group_label>NRTI sparing arm</arm_group_label>
    <other_name>Prezista</other_name>
    <other_name>Norvir</other_name>
    <other_name>Intelence</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV-1 infected males or females&#xD;
&#xD;
          -  over 18 years of age&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  currently receiving a stable antiretroviral regimen comprising of:&#xD;
&#xD;
          -  two or more licensed NRTIs&#xD;
&#xD;
          -  one licensed NNRTI or boosted protease inhibitor&#xD;
&#xD;
          -  no previous protease inhibitor resistance documented on HIV-1 genotypic resistance&#xD;
             testing&#xD;
&#xD;
          -  failure of current antiretroviral regimen due to:&#xD;
&#xD;
          -  toxicity, intolerance or virological failure if receiving an NNRTI containing regimen&#xD;
             at screening&#xD;
&#xD;
          -  toxicity or intolerance if receiving a boosted-protease inhibitor regimen at screening&#xD;
             (with plasma HIV RNA &lt; 400 copies/mL at screening)&#xD;
&#xD;
          -  willing to modify antiretroviral therapy, in accordance with the randomisation&#xD;
             assignment&#xD;
&#xD;
          -  no previous exposure to etravirine&#xD;
&#xD;
          -  subjects in good health upon medical history, physical exam, and laboratory testing in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  have no serologic evidence of active HBV infection evidenced by negative hepatitis B&#xD;
             surface antigen&#xD;
&#xD;
          -  female subjects who are heterosexually active and of childbearing potential (i.e., not&#xD;
             surgically sterile or at least two years post menopausal) must practice contraception&#xD;
             as follows from screening through completion of the study:&#xD;
&#xD;
          -  barrier contraceptives (condom, diaphragm with spermicide)&#xD;
&#xD;
          -  IUD or Depo PLUS a barrier contraceptive&#xD;
&#xD;
          -  female subjects of childbearing potential must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current alcohol abuse or drug dependence&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  active opportunistic infection or significant co-morbidities&#xD;
&#xD;
          -  current prohibited concomitant medication&#xD;
&#xD;
          -  a likelihood of diminished response to any of the study treatment arms, in the opinion&#xD;
             of the investigator, based on HIV genotypic resistance testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan Winston, MB ChB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's Hospital</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>May 6, 2010</study_first_submitted>
  <study_first_submitted_qc>May 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2010</study_first_posted>
  <last_update_submitted>March 23, 2015</last_update_submitted>
  <last_update_submitted_qc>March 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

